The aim of the Human Fertilisation and Embryology Act 2008 is to provide "revised and updated legislation for assisted reproduction and changes to the regulation and licensing of the use of embryos in research and therapy". 1 However, its "provision for research on different types of embryos" raises a number of serious scientific questions and ethical dilemmas, principally because it permits the controlled creation and use of admixed animal-human embryos, by replacing the nuclei of animal eggs with human nuclei or cells, in order to increase the availability of human embryonic stem cells for research on a wide range of serious diseases. 2 The supporters of the proposal claimed that vital medical research would not be possible, unless human stem cells could be made more readily available, that only human embryonic stem cells would be suitable, and that the creation of admixed embryos would be the best way of producing them. The counter-argument was that the ethical pitfalls involved could be avoided, as stem cells could be produced from post-embryonic human tissues, including the umbilical cord and bone-marrow.
There was much lively debate in Parliament and in the media, 3 and Colin Blakemore, former head of the Medical Research Council, even went so far as to say that the new legislation would be "essential, if Britain is to maintain its responsible leadership in stem-cell research". 4 However, it also emerged that the UK was "not investing enough in research on human adult stem cells, as a result of which we will fall behind in the development of new therapies for many serious diseases, and some of our best scientists will emigrate to work in countries where their work is viewed more favourably". 3 The force of the Scientific Establishment prevailed, and the new Act received the Royal Assent on 13 November 2008. However, it was already becoming clear that developments elsewhere in the world would destroy the claim that admixed animal-human embryos could be considered to be essential for dealing with the complexity of dis-eases which threaten the length and quality of human lives. In an influential article on Endless Possibil ities: Stem Cells and the Vision for Toxicity Testing in the 21st Century, 5 Chapin and Stedman referred to the great potential importance of the production of induced pluripotent stem (iPS) cells derived from differentiated cells, proclaimed by Science to be the Breakthrough of the Year in 2008. 6 These issues have been brought to the fore again by the announcement of the award of the 2012 Nobel Prize for Physiology or Medicine jointly to Professor Sir John Gurdon and Professor Shinya Yamanaka. 7, 8 Yamanaka and his colleagues at Kyoto Uni versity, Japan, studied mouse embryonic stem cells, and identified a number of transcription factors that might be involved in the maintenance of their pluripotency. They selected a set of 24 factors, and introduced the genes for encoding them into skin fibroblasts. Eventually, they identified a combination of only four transcription factors that could convert mouse embryonic fibroblasts into iPS cells. 9 Shortly afterwards, human iPS cells were first produced by Yamanaka and his colleagues 10 and by James Thomson and his team at Madison, Wisconsin, USA. Yamanaka et al. used the established four-factor combination, whereas Yu et al. used a different transcription factor combination. 11 Note that this work was published before the passage of the new legislation in the UK.
There is now a massive investment in iPS cell technology all over the world, as indicated by 1,510,00 results from a Google search made on 29 October 2012. An up-to-date indication of the breath taking promise of this research can be found in the scientific background to the 2012 Nobel Prize. 12 There are, of course, many unresolved questions about the nature of iPS cells and their uses, some of which have recently been discussed by Yamanaka himself, in a thoughtful review. 13 One development of particular interest is StemBANCC (Stem Cells for Biological Assays of 
Breakthroughs with iPS cells make the creation of admixed embryos unnecessary and indefensible
Novel Drugs and Predictive Toxicology), a €52 million Innovative Medicines Initiative (IMI) project, which will have had its kick-off meeting on 30-31 October 2012, in Basel, Switzerland. It involves 25 academic partners and 11 industry partners, in 11 countries, and its principal aim is the development of human iPS cells as a platform for drug discovery. It will focus on "eight major diseases of our time: Alzheimer's, Parkinson's, Autism, Schizo phrenia, Bipolar, Migraine, Pain and Diabetes", 14 and its key objectives are: to develop an unparalleled resource of iPS cells from patients with well-characterised disorders; to overcome current bottlenecks in stem cell re-programming and differentiation; to identify molecular and cellular phenotypes of disease in stem cell models; and to translate its findings into novel drug screening efficacy and toxicity assays.
The patriotic part of me is particularly pleased that the University of Oxford is the academic lead institution for the StemBANCC project, via a consortium of eight departments. This clearly demonstrates that Blakemore's fears were unfounded.
Meanwhile, it is hard to know whether any research on admixed embryos is still going on. In July 2011, a report in the MailOnline indicated that three laboratories had been granted licences to create such embryos, but that they had all stopped such work, because of lack of funding. 15 Let us hope that the grant-giving bodies will continue to invest their resources in scientifically stronger and less controversial endeavours. 
Professor Michael Balls Chairman of the FRAME Trustees

Note added in proof
In an article in The Times on 5 November 2012, a entitled If scientists are silent, loony ideas will win, Colin Blakemore lauds the success of scientists in swinging the balance in the media and in Parliament, in favour of the creation of admixed animal-human embryos. Their argument was that this would be essential for the isolation and use of human stem cells. However, as was said when the Human Fertilisation and Embryology Bill was under discussion, the development of the iPS cell technology negated that argument, and the truth of that has been borne out since then, by a vast amount of excellent work on iPS cells from adult human tissues and the award of the Nobel Prize to Shinya Yamanaka. Meanwhile, there appear to have been very few attempts to produce admixed embryos. Blakemore should realise that scientists, as well as non-scientists, can have loony ideas, and he would do us all a service, if he kept his own to himself.
